• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncCook.pdf
    Size:
    117.3Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Cook, Natalie
    Blagden, S.
    Lopez, J.
    Sarker, D.
    Greystoke, A.
    Harris, N.
    Kazmi, F.
    Naderi, A.
    Nintos, G.
    Ortega-Franco, Ana
    Pihlak, Rille
    Shinde, R.
    Goodwin, L.
    Phillips, C.
    Robertson, J.
    Saunders, A.
    Tilston, C.
    Woodcock, S.
    Plummer, R.
    Show allShow less
    Affiliation
    Experimental Cancer Medicine Centre, The University of Manchester and the Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background Dysregulated Wnt signalling drives several cancers through effects on proliferation, fibrosis and immune evasion. RXC004 is a novel small molecule inhibitor of the protein-serine O-palmitoyltransferase, PORCN, which is required for post-translational modification of Wnt ligands and downstream signaling. RXC004 has potential for monotherapy efficacy in Wnt pathway activated tumours: ?5% pancreatic and ? 8% microsatellite stable colorectal (CRC) cancers with RNF-43 mutations or R-Spondin fusions, and thymus and biliary tract (BTC) cancers with high Wnt ligand activity. Methods This open label, 3+3 dose escalation study was one module of a multi-modular adaptive design protocol (NCT03447470). Following a single dose with a 7-day washout, patients received RXC004 once daily in 21-day cycles. The primary objectives were to assess safety and tolerability and define a recommended phase 2 dose of RXC004. Secondary objectives were PK and RECIST response. Pharmacodynamic markers included skin Wnt pathway (Axin2) suppression. Results Between 05/02/2018 and 21/06/2021, 25 patients with advanced cancers received RXC004. The first patient, who received 10mg daily, discontinued due to diarrhoea and an asymptomatic clavicle fracture was found on follow up. The half-life (T1/2) and exposure were higher than predicted from preclinical models. The study was paused and restarted at 0.5mg. Subsequently, 1mg, 1.5mg, 2mg and 3mg doses were evaluated. Patients received denosumab 120 mg s.c monthly to prevent bone adverse events [AEs]. For doses <3mg, the most common treatment related AEs were fatigue, nausea, dysgeusia, vomiting and anorexia. No grade 4/5 AEs or bone fragility events were reported. Exposure was dose proportional and median T1/2 was 14.5h. Exposures above the preclinical model IC50 were observed at all doses, as was Axin2 suppression. Five patients, all with Wnt pathway activated tumours [2 BTC, 1 Thymus, 1 mutRNF43 CRC and 1 RSPO fusion CRC] had stable disease, in one case for up to 26 weeks. Conclusions In patients with unselected cancers, RXC004 was safe and tolerated at doses up to 2mg/day, supporting phase 2 development in selected patients with Wnt pathway activated tumours. Studies will open in 2021.
    Citation
    Cook N, Blagden S, Lopez J, Sarker D, Greystoke A, Harris N, et al. 517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours. Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S586�7.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624707
    DOI
    10.1016/j.annonc.2021.08.1039
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.1039
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.1039
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.